



Notification 6389

Implementation Date

10/5/2023

Category

HCPCS - Drugs & Biologicals

Topic

Louisiana Medicaid - Injection, octreotide, depot form for intramuscular injection, 1 mg

What is changing?

We limit reimbursement of charges for injection, octreotide, depot form for intramuscular injection, 1 mg, to no more than 1 administration every 3 weeks if billed with 1 of the following indications:

- Carcinoid/neuroendocrine tumors
- Vasoactive intestinal peptide tumor (VIPoma)

Language

English

Impacted Products

- Medicaid – Louisiana

Why is Humana making this change?

The above limitations for injection, octreotide, depot form for intramuscular injection, 1 mg, were established by the FDA-approved package insert and prescribing information and pharmaceutical compendia.